- Record: found
- Abstract: not found
- Article: not found
Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d5544745e57">Although vaccination is the primary strategy against
severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), rheumatologic patients on B-cell depleting agent rituximab
may have a suboptimal response. Tixagevimab and cilgavimab (Evusheld) could be administered
under Food and Drug Administration emergency use authorization as pre-exposure prophylaxis.
</p>